Cargando…

Hypertension Contributes to Neuropathy in Patients With Type 1 Diabetes

BACKGROUND: Diabetic peripheral neuropathy (DPN) can lead to foot ulceration and amputation. There are currently no disease-modifying therapies for DPN. The aim of this study was to determine if hypertension contributes to DPN in patients with type 1 diabetes mellitus (T1DM). METHODS: Subjects with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponirakis, Georgios, Petropoulos, Ioannis N, Alam, Uazman, Ferdousi, Maryam, Asghar, Omar, Marshall, Andrew, Azmi, Shazli, Jeziorska, Maria, Mahfoud, Ziyad R, Boulton, Andrew J M, Efron, Nathan, Nukada, Hitoshi, Malik, Rayaz A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636691/
https://www.ncbi.nlm.nih.gov/pubmed/31013342
http://dx.doi.org/10.1093/ajh/hpz058
Descripción
Sumario:BACKGROUND: Diabetic peripheral neuropathy (DPN) can lead to foot ulceration and amputation. There are currently no disease-modifying therapies for DPN. The aim of this study was to determine if hypertension contributes to DPN in patients with type 1 diabetes mellitus (T1DM). METHODS: Subjects with T1DM (n = 70) and controls (n = 78) underwent a comprehensive assessment of DPN. RESULTS: Hypertension was present in 40 of 70 T1DM subjects and 20 of 78 controls. Hypertension was associated with abnormal nerve conduction parameters (P = 0.03 to <0.001), increased vibration perception threshold (P = 0.01) and reduced corneal nerve fiber density and length (P = 0.02) in subjects with T1DM. However, after adjusting for confounding factors only tibial compound motor action potential and nerve conduction velocity were associated with hypertension (P = 0.03) and systolic blood pressure (P < 0.01 to <0.0001). Hypertension had no effect on neuropathy in subjects without diabetes. CONCLUSIONS: This study shows that hypertension is associated with impaired nerve conduction in T1DM. It supports previous small trials showing that angiotensin-converting enzyme inhibitors improve nerve conduction and advocates the need for larger clinical trials with blood pressure lowering agents in DPN.